J. Goldman & Co’s Gilead Sciences GILD Stock Holding History

J. Goldman & Co’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-74,912	Closed	-$10.4M	–	786
2026 Q1	$10.4M	Buy	+74,912	New	+$10.5M	0.3%	105
2025 Q4	–	Sell	-188,390	Closed	-$22.9M	–	620
2025 Q3	$20.9M	Buy	188,390 +58,947	+46%	+$6.7M	0.53%	48
2025 Q2	$14.4M	Buy	129,443 +51,591	+66%	+$5.49M	0.34%	99
2025 Q1	$8.72M	Buy	77,852 +74,479	+2,208%	+$7.69M	0.22%	142
2024 Q4	$312K	Sell	3,373 -60,064	-95%	-$5.41M	0.01%	389
2024 Q3	$5.32M	Buy	63,437 +27,702	+78%	+$2.11M	0.15%	151
2024 Q2	$2.45M	Buy	+35,735	New	+$2.38M	0.07%	232
2024 Q1	–	Sell	-23,862	Closed	-$1.93M	–	444
2023 Q4	$1.93M	Buy	+23,862	New	+$1.86M	0.08%	190
2023 Q1	–	Sell	-176,697	Closed	-$15.2M	–	410
2022 Q4	$15.2M	Buy	+176,697	New	+$14M	0.75%	40
2017 Q2	–	Sell	-10,800	Closed	-$734K	–	349
2017 Q1	$734K	Buy	+10,800	New	+$759K	0.04%	267

Other funds holding GILD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

J. Goldman & Co's GILD Position: Q2 2026 in Review

J. Goldman & Co sold out of Gilead Sciences (GILD) in Q2 2026, closing a stake of 74,912 shares — an estimated $10.4M sold.

J. Goldman & Co first reported a position in GILD in Q1 2017 and held it in 10 quarters. The position peaked at $20.9M in Q3 2025. 2,274 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

J. Goldman & Co reported no remaining Gilead Sciences position as of Q2 2026 after selling out during the quarter.
J. Goldman & Co sold 74,912 Gilead Sciences shares in Q2 2026, an estimated $10.4M.
J. Goldman & Co first reported a position in Gilead Sciences in Q1 2017 and held it in 10 quarters.
J. Goldman & Co's Gilead Sciences position peaked at $20.9M in Q3 2025.
2,274 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on J. Goldman & Co's 13F filing for Q2 2026, filed 14 Aug 2026.